Tiagabine

Evidence Level: N/A Predicted Indications: 0

Table of Contents

  1. Tiagabine
    1. Pharmacist Assessment Report
    2. Tiagabine: Known uses and market status in India
    3. Summary
    4. Quick overview
    5. Known uses among the model’s candidates
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
    6. India Market Information
    7. Safety Considerations
    8. Disclaimer

Pharmacist Assessment Report

Tiagabine: Known uses and market status in India

Summary

The TxGNN model produced candidates for Tiagabine, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. This page lists the known uses and the market status in India.

Quick overview

Item Content
New predicted indications None (all traceable model candidates are known uses)
Known uses among model candidates 0
Evidence level Not applicable
India Market Status Listed in a compiled Indian medicine price dataset (1 of 1) – CDSCO approval status is not included in this data
Number of Listed Products 1 (valid: 1)

Known uses among the model’s candidates

Approved (supported by a licence or label)

Indication Source
none none
Indication Approved category
none none

Relations recorded in the knowledge graph (no approval found)

Indication
none

India Market Information

Licence Product Dosage form Status
229036 Tigatel 8mg Tablet strip of 10 tablets Valid

Safety Considerations

  • Contraindications (from knowledge graph, not label text): anxiety disorder, neurotic disorder, dysthymic disorder, liver disease, gallbladder disease.
  • Visual safety: The literature includes a review of visual field effects of tiagabine and vigabatrin (PMID 12588906). Visual function should be reviewed before any further consideration in a visual condition.
  • Seizure exacerbation: GABAergic antiepileptic drugs, including tiagabine, can aggravate seizures or provoke status epilepticus in some epilepsy types, particularly generalized epilepsies (PMID 26210064).
  • Drug Interactions: 97 interactions were identified. The main moderate-level ones are:
    • Aprepitant
    • Morphine (including liposomal)
    • Dronabinol
    • Nabilone
    • Metoclopramide
    • Opium

    Interactions with other drugs, such as pantoprazole, omeprazole, metformin and ondansetron, are listed with unknown severity.

Please refer to the package insert for full warnings, as label-level data was not available.


Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.



This site uses Just the Docs, a documentation theme for Jekyll.